NEWS
CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim
CVRx, Inc. (NASDAQ: CVRX) has announced the publication of new data in JACC: Heart Failure, showcasing the long-term quality of life benefits of Barostim for heart failure patients with reduced ejection fraction. The data, from the BeAT-HF trial, demonstrates durable improvements up to 24 months in Minnesota Living with Heart Failure (MLWHF) and EuroQual-5D (EQ-5D) quality of life measures.
Patients receiving Barostim plus guideline-directed medical therapy (GDMT) reported significant improvements in physical and psychosocial measures compared to those receiving GDMT alone. These improvements included better ability to work around the house, sleep, and engage in activities with friends and family, as well as reduced depression and feelings of being a burden. Physically, patients reported less shortness of breath, fatigue, and pain, with increased mobility and ability to perform usual activities.
Patients receiving Barostim plus guideline-directed medical therapy (GDMT) reported significant improvements in physical and psychosocial measures compared to those receiving GDMT alone. These improvements included better ability to work around the house, sleep, and engage in activities with friends and family, as well as reduced depression and feelings of being a burden. Physically, patients reported less shortness of breath, fatigue, and pain, with increased mobility and ability to perform usual activities.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1399Followers
79Following
10KVisitors
Follow